Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.35 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | RHOA | P61586 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449584 | 1.00 | SYK (0.36) | SYKCSNK1A1ORAI1TRPC1TRPC3 | |
| SCHEMBL3447647 | 0.92 | SYK (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3447650 | 0.92 | SYK (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3448630 | 0.87 | MAPT (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3448633 | 0.87 | MAPT (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3448103 | 0.86 | SYK (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3448111 | 0.86 | SYK (0.37) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3447185 | 0.85 | KCNN3 (0.42) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3447183 | 0.85 | KCNN3 (0.42) | SYKCSNK1A1PIM2AURKAGSK3A | |
| SCHEMBL3448515 | 0.84 | PIM2 (0.40) | CSNK1A1PIM2AURKAGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885CSNK1A1 1378/4885ORAI1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.